Related Experiment Videos
Recent developments in adjuvants for vaccines against infectious diseases
D T O'Hagan1, M L MacKichan, M Singh
1Chiron Corporation, Immunology and Infectious Diseases, 4560 Horton Street, Emeryville, CA 94608, USA. derek_o'hagan@chiron.com
Biomolecular Engineering
|September 22, 2001
Summary
New vaccine adjuvants are crucial as next-generation vaccines are less immunogenic. Understanding adjuvant mechanisms, like delivery systems and immunostimulatory adjuvants, is key to developing more effective vaccines.
Area of Science:
- Immunology
- Vaccinology
Background:
- Next-generation vaccines (recombinant protein, DNA) show reduced immunogenicity compared to traditional vaccines.
- This necessitates the development of novel and enhanced vaccine adjuvants to improve immune responses.
Purpose of the Study:
- To review the classification and mechanisms of action of current vaccine adjuvants.
- To highlight the need for further research into adjuvant mechanisms for rational design.
Main Methods:
- Classification of adjuvants into two main categories: vaccine delivery systems and immunostimulatory adjuvants.
- Discussion of how these adjuvants interact with the innate and adaptive immune systems.
- Exploration of combined adjuvant delivery systems for enhanced antigen presentation.
Main Results:
- Vaccine delivery systems (emulsions, liposomes) primarily target antigens to antigen-presenting cells (APCs).
- Immunostimulatory adjuvants (LPS, MPL, CpG DNA) activate innate immunity via pathogen-associated molecular patterns (PAMPs).
- Activated innate immunity is essential for driving and focusing acquired immune responses.
Conclusions:
- Further research is required to elucidate the precise mechanisms of action for existing adjuvants.
- Development of potent adjuvants could enable vaccines against challenging pathogens like HIV.
- New adjuvants may facilitate the development of mucosal vaccines.